urmjУральский медицинский журналUral Medical Journal2949-4389Ural State Medical University10.52420/2071-5943-2024-23-1-37-45JGAKXHurmj-1424Research ArticleОригинальные статьи | Original articlesOriginal articlesПерспективная роль онкомаркеров СА 19-9 и СА 125 в диагностике прогрессирующего фиброза легкихThe Promising Role of Oncomarkers CA 19-9 and CA 125 in the Diagnosis of Progressive Pulmonary Fibrosishttps://orcid.org/0000-0002-9146-0904ЩепихинЕ. И.ShchepikhinE. I.

Евгений Игоревич Щепихин — заведующий дифференциально-диагностическим отделением Клиники № 1, врач-пульмонолог, аспирант отделения дифференциальной диагностики туберкулеза легких и экстракорпоральных методов лечения

Москва

Evgeniy I. Shchepikhin - Head of the Differential-Diagnostic Department, Pulmonologist, Postgraduate Student of the Department Differential Diagnosis of Tuberculosis of the Lungs

Moscow

shhepikhin11@yandex.ruhttps://orcid.org/0000-0002-1908-5601ШмелёвЕ. И.ShmelevE. I.

Евгений Иванович Шмелёв — доктор медицинских наук, профессор, главный научный сотрудник отдела дифференциальной диагностики туберкулеза легких и экстракорпоральных методов лечения

Москва

Evgeniy I. Shmelev — Doctor of Sciences (Medicine), Professor, Chief] Researcher of the Differential Diagnostics Department of Tuberculosis of the Lughs

Moscow

cniit@ctri.tuhttps://orcid.org/0000-0002-2494-9275ЭргешовА. Э.ErgeshovA. E.

Атаджан Эргешович Эргешов — доктор медицинских наук, профессор, член-корреспондент Российской академии наук, директор, профессор кафедры фтизиатрии

Москва

Atadzhan E. Ergeshov — Doctor of Sciences (Medicine), Professor, Corresponding Member of the Russian Academy of Sciences, Director, Professor of the Department of Phthisiology

Moscow

cniit@ctri.tuЦентральный научно-исследовательский институт туберкулеза ; Московский областной клинический противотуберкулезный диспансерРоссияCentral Tuberculosis Research Institute ; Moscow Regional Clinical Tuberculosis DispensaryRussian FederationЦентральный научно-исследовательский институт туберкулезаРоссияCentral Tuberculosis Research InstituteRussian FederationЦентральный научно-исследовательский институт туберкулеза ; Российский университет медициныРоссияCentral Tuberculosis Research Institute ; Russian University of MedicineRussian Federation2024060320242313745Copyright © Щепихин Е.И., Шмелёв Е.И., Эргешов А.Э., 20242024Щепихин Е.И., Шмелёв Е.И., Эргешов А.Э.Shchepikhin E.I., Shmelev E.I., Ergeshov A.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.umjusmu.ru/jour/article/view/1424

Цель исследования — установить роль сывороточных гликопротеинов СА 19-9 и СА 125 как потенциальных неинвазивных биомаркеров прогрессирующего фиброза при интерстициальных заболеваниях легких.

Материалы и методы

Материалы и методы. В поперечное обсервационное исследование включено 77 пациентов с интерстициальными заболеваниями легких (ИЗЛ). На основании наличия или отсутствия признаков прогрессирования за предшествующие 6 месяцев пациенты были разделены на 2 группы (пациенты с прогрессирующим легочным фиброзом и пациенты с непрогрессирующими ИЗЛ). Всем пациентам выполнялись форсированная спирометрия, бодиплетизмография, диффузионный тест, компьютерная томография органов грудной клетки, исследование сывороточной концентрации СА 19-9 и СА 125.

Результаты

Результаты. В группе пациентов с прогрессирующим фибротическим фенотипом ИЗЛ выявлен более высокий уровень СА 19-9 и СА 125. Показана корреляция изучаемого уровня онкомаркеров с параметрами легочной функции и выраженностью интерстициальных изменений в легких по данным компьютерной томографии органов грудной клетки (Warrick-тест).

Заключение

Заключение. Полученные в результате проведенного исследования данные демонстрируют потенциальные возможности сывороточных онкомаркеров CА 19-9 и СА 125 в качестве неинвазивного инструмента в диагностике прогрессирующего фиброза легких и требуют дальнейших исследований и проспективного наблюдения для оценки диагностической и прогностической роли исследуемых биомаркеров, а также определения их места в клинической практике.

Purpose of the study to study the role of serum glycoproteins CA 19–9 and CA 125 as a potential non-invasive biomarker of progressive fibrosis in interstitial lung diseases.

Materials and methods

Materials and methods. The study included 77 patients with interstitial diseases. Based on the presence/absence of signs of progression over the previous 6 months, patients were divided into 2 groups. All patients underwent forced spirometry, body plethysmography, diffusion test, computed tomography of the chest, and a study of serum concentrations of CA 19-9 and CA 125.

Results

Results. In the group of patients with a progressive fibrotic phenotype of interstitial lung diseases (ILD), higher levels of CA 19-9 and CA 125 were detected. A correlation of the studied level of tumor markers with parameters of pulmonary function and the severity of interstitial changes in lung changes according to computed tomography of the chest was shown (Warrick test).

Conclusion

Conclusion. The data obtained demonstrate the capabilities of non-invasive diagnosis of PF-ILD and require further research and prospective observation to assess the diagnostic and prognostic role of the studied biomarkers, as well as determine their place in clinical practice.

интерстициальные заболевания легкихлегочный фиброзмикроциркуляцияCOVID-19онкомаркерыпрогрессирующий фибротический фенотипбиомаркерыinterstitial lung diseasespulmonary fibrosismicrocirculationCOVID-19tumor markersprogressive fibrotic phenotypebiomarkersReferencesWijsenbeek M, Cottin V. Spectrum of fibrotic lung diseases. The New England Journal of Medicine. 2020;383(10):958–968. DOI: https://doi.org/10.1056/NEJMra2005230.Wijsenbeek M, Cottin V. Spectrum of fibrotic lung diseases. The New England Journal of Medicine. 2020;383(10):958–968. DOI: https://doi.org/10.1056/NEJMra2005230.Chuchalin AG, Avdeev SN, Aisanov ZR, Belevskiy AS, Demura SA, Il’kovich MM, et al. Diagnosis and treatment of idiopathic pulmonary fibrosis. Federal Guidelines. PULMONOLOGIYA. 2016;26(4):399–419. (In Russ.). DOI: https://doi.org/10.18093/0869-0189-2016-26-4-399-419.Chuchalin AG, Avdeev SN, Aisanov ZR, Belevskiy AS, Demura SA, Il’kovich MM, et al. Diagnosis and treatment of idiopathic pulmonary fibrosis. Federal Guidelines. PULMONOLOGIYA. 2016;26(4):399–419. (In Russ.). DOI: https://doi.org/10.18093/0869-0189-2016-26-4-399-419.Adegunsoye A, Ryerson CJ. Diagnostic classification of interstitial lung disease in clinical practice. Clinics in Chest Medicine. 2021;42(2):251–261. DOI: https://doi.org/10.1016/j.ccm.2021.03.002.Adegunsoye A, Ryerson CJ. Diagnostic classification of interstitial lung disease in clinical practice. Clinics in Chest Medicine. 2021;42(2):251–261. DOI: https://doi.org/10.1016/j.ccm.2021.03.002.Brown KK, Martinez FJ, Walsh SLF, Thannickal VJ, Prasse A, Schlenker-Herceg R, et al. The natural history of progressive fibrosing interstitial lung diseases. European Respiratory Journal. 2020;55(6):2000085. DOI: https://doi.org/10.1183/13993003.00085-2020.Brown KK, Martinez FJ, Walsh SLF, Thannickal VJ, Prasse A, Schlenker-Herceg R, et al. The natural history of progressive fibrosing interstitial lung diseases. European Respiratory Journal. 2020;55(6):2000085. DOI: https://doi.org/10.1183/13993003.00085-2020.Cottin V, Hirani NA, Hotchkin DL, Nambiar AM, Ogura T, Otaolaet M, et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. European Respiratory Review. 2018;27(150):180076. DOI: https://doi.org/10.1183/16000617.0076-2018.Cottin V, Hirani NA, Hotchkin DL, Nambiar AM, Ogura T, Otaolaet M, et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. European Respiratory Review. 2018;27(150):180076. DOI: https://doi.org/10.1183/16000617.0076-2018.Mei Q, Liu Z, Zuo H, Yang Z, Qu J. Idiopathic pulmonary fibrosis: An update on pathogenesis. Frontiers in Pharmacology. 2022;12:797292. DOI: https://doi.org/10.3389/fphar.2021.797292.Mei Q, Liu Z, Zuo H, Yang Z, Qu J. Idiopathic pulmonary fibrosis: An update on pathogenesis. Frontiers in Pharmacology. 2022;12:797292. DOI: https://doi.org/10.3389/fphar.2021.797292.Confalonieri P, Volpe MC, Jacob J, Maiocchi S, Salton F, Ruaro B, et al. Regeneration or repair? The role of alveolar epithelial cells in the pathogenesis of idiopathic pulmonary fibrosis (IPF). Cells. 2022;11(13):2095. DOI: https://doi.org/10.3390/cells11132095.Confalonieri P, Volpe MC, Jacob J, Maiocchi S, Salton F, Ruaro B, et al. Regeneration or repair? The role of alveolar epithelial cells in the pathogenesis of idiopathic pulmonary fibrosis (IPF). Cells. 2022;11(13):2095. DOI: https://doi.org/10.3390/cells11132095.Okuda R, Aoshiba K, Matsushima H, Ogura T, Okudela K, Ohashi K. Cellular senescence and senescence-associated secretory phenotype: Comparison of idiopathic pulmonary fibrosis, connective tissue disease-associated interstitial lung disease, and chronic obstructive pulmonary disease. Journal of Thoracic Disease. 2019;11(3):857–864. DOI: https://doi.org/10.21037/jtd.2019.02.11.Okuda R, Aoshiba K, Matsushima H, Ogura T, Okudela K, Ohashi K. Cellular senescence and senescence-associated secretory phenotype: Comparison of idiopathic pulmonary fibrosis, connective tissue disease-associated interstitial lung disease, and chronic obstructive pulmonary disease. Journal of Thoracic Disease. 2019;11(3):857–864. DOI: https://doi.org/10.21037/jtd.2019.02.11.Zhang H, Chen L, Wu L, Huang J, Li H, Wang X, et al. Diagnostic and prognostic predictive values of circulating KL-6 for interstitial lung disease: A PRISMA-compliant systematic review and meta-analysis. Medicine. 2020;99(16): e19493. DOI: https://doi.org/10.1097/MD.0000000000019493.Zhang H, Chen L, Wu L, Huang J, Li H, Wang X, et al. Diagnostic and prognostic predictive values of circulating KL-6 for interstitial lung disease: A PRISMA-compliant systematic review and meta-analysis. Medicine. 2020;99(16): e19493. DOI: https://doi.org/10.1097/MD.0000000000019493.Jehn LB, Costabel U, Boerner E, Wälscher J, Theegarten D, Taube C, et al. Serum KL-6 as a biomarker of progression at any time in fibrotic interstitial lung disease. Journal of Clinical Medicine. 2023;12(3):1173. DOI: https://doi.org/10.3390/jcm12031173.Jehn LB, Costabel U, Boerner E, Wälscher J, Theegarten D, Taube C, et al. Serum KL-6 as a biomarker of progression at any time in fibrotic interstitial lung disease. Journal of Clinical Medicine. 2023;12(3):1173. DOI: https://doi.org/10.3390/jcm12031173.Hirasawa Y, Kohno N, Yokoyama A, Inoue Y, Abe M, Hiwada K. KL-6, a human MUC1 mucin, is chemotactic for human fibroblasts. American Journal of Respiratory Cell and Molecular Biology. 1997;17(4):501–507. DOI: https://doi.org/10.1165/ajrcmb.17.4.2253.Hirasawa Y, Kohno N, Yokoyama A, Inoue Y, Abe M, Hiwada K. KL-6, a human MUC1 mucin, is chemotactic for human fibroblasts. American Journal of Respiratory Cell and Molecular Biology. 1997;17(4):501–507. DOI: https://doi.org/10.1165/ajrcmb.17.4.2253.Zhong D, Wu C, Bai J, et al. Comparative diagnostic efficacy of serum Krebs von den Lungen-6 and surfactant D for connective tissue disease-associated interstitial lung diseases: A meta-analysis. Medicine. 2020;99(16): e19695. DOI: https://doi.org/10.1097/MD.0000000000019695.Zhong D, Wu C, Bai J, et al. Comparative diagnostic efficacy of serum Krebs von den Lungen-6 and surfactant D for connective tissue disease-associated interstitial lung diseases: A meta-analysis. Medicine. 2020;99(16): e19695. DOI: https://doi.org/10.1097/MD.0000000000019695.Wang K, Ju Q, Cao J, Tang W, Zhang J. Impact of serum SP-A and SP-D levels on comparison and prognosis of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. Medicine. 2017;96(23): e7083. DOI: https://doi.org/10.1097/MD.0000000000007083.Wang K, Ju Q, Cao J, Tang W, Zhang J. Impact of serum SP-A and SP-D levels on comparison and prognosis of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. Medicine. 2017;96(23): e7083. DOI: https://doi.org/10.1097/MD.0000000000007083.Elhai M, Avouac J, Allanore Y. Circulating lung biomarkers in idiopathic lung fibrosis and interstitial lung diseases associated with connective tissue diseases: Where do we stand? Seminars in Arthritis and Rheumatism. 2020;50(3):480–491. DOI: https://doi.org/10.1016/j.semarthrit.2020.01.006.Elhai M, Avouac J, Allanore Y. Circulating lung biomarkers in idiopathic lung fibrosis and interstitial lung diseases associated with connective tissue diseases: Where do we stand? Seminars in Arthritis and Rheumatism. 2020;50(3):480–491. DOI: https://doi.org/10.1016/j.semarthrit.2020.01.006.Kwon BS, Kim ES, Lim SY, Song MJ, Kim YW, Kim HJ, et al. The significance of elevated tumor markers among patients with interstitial lung diseases. Scientific Reports. 2022;12(1):16702. DOI: https://doi.org/10.1038/s41598-022-20683-w.Kwon BS, Kim ES, Lim SY, Song MJ, Kim YW, Kim HJ, et al. The significance of elevated tumor markers among patients with interstitial lung diseases. Scientific Reports. 2022;12(1):16702. DOI: https://doi.org/10.1038/s41598-022-20683-w.Chuchalin AG, Avdeev SN, Aisanov ZR, Baranova OP, Borisov SE, Geppe NA, et al. Sarcoidosis: Federal clinical guidelines for diagnosis and treatment. PULMONOLOGIYA. 2022;32(6):806–833. (In Russ.). DOI: https://doi.org/10.18093/0869-0189-2022-32-6-806-833.Chuchalin AG, Avdeev SN, Aisanov ZR, Baranova OP, Borisov SE, Geppe NA, et al. Sarcoidosis: Federal clinical guidelines for diagnosis and treatment. PULMONOLOGIYA. 2022;32(6):806–833. (In Russ.). DOI: https://doi.org/10.18093/0869-0189-2022-32-6-806-833.Baughman RP, Valeyre D, Korsten P, Mathioudakis AG, Wuyts WA, Wells A, et al. ERS clinical practice guidelines on treatment of sarcoidosis. European Respiratory Journal. 2021;58(6):2004079. DOI: https://doi.org/10.1183/13993003.04079-2020.Baughman RP, Valeyre D, Korsten P, Mathioudakis AG, Wuyts WA, Wells A, et al. ERS clinical practice guidelines on treatment of sarcoidosis. European Respiratory Journal. 2021;58(6):2004079. DOI: https://doi.org/10.1183/13993003.04079-2020.Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. American Journal of Respiratory and Critical Care Medicine. 2018;198(5):e44–e68. DOI: https://doi.org/10.1164/rccm.201807-1255ST.Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. American Journal of Respiratory and Critical Care Medicine. 2018;198(5):e44–e68. DOI: https://doi.org/10.1164/rccm.201807-1255ST.Jee AS, Sheehy R, Hopkins P, Corte TJ, Grainge C, Troy LK, et al. Diagnosis and management of connective tissue disease-associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand. Respirology. 2021;26(1):23–51. DOI: https://doi.org/10.1111/resp.13977.Jee AS, Sheehy R, Hopkins P, Corte TJ, Grainge C, Troy LK, et al. Diagnosis and management of connective tissue disease-associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand. Respirology. 2021;26(1):23–51. DOI: https://doi.org/10.1111/resp.13977.Raghu G, Remy-Jardin M, Ryerson CJ, Myers JL, Kreuter M, Vasakova M, et al. Diagnosis of hypersensitivity pneumonitis in adults. An official ATS/JRS/ALAT clinical practice guideline. American Journal of Respiratory and Critical Care Medicine. 2020;202(3):e36–e69. DOI: https://doi.org/10.1164/rccm.202005-2032ST. Erratum in: American Journal of Respiratory and Critical Care Medicine. 2021;203(1):150–151. Erratum in: American Journal of Respiratory and Critical Care Medicine. 2022;206(4):518.Raghu G, Remy-Jardin M, Ryerson CJ, Myers JL, Kreuter M, Vasakova M, et al. Diagnosis of hypersensitivity pneumonitis in adults. An official ATS/JRS/ALAT clinical practice guideline. American Journal of Respiratory and Critical Care Medicine. 2020;202(3):e36–e69. DOI: https://doi.org/10.1164/rccm.202005-2032ST. Erratum in: American Journal of Respiratory and Critical Care Medicine. 2021;203(1):150–151. Erratum in: American Journal of Respiratory and Critical Care Medicine. 2022;206(4):518.Warrick JH, Bhalla M, Schabel SI, Silver RM. High resolution computed tomography in early scleroderma lung disease. The Journal of Rheumatology. 1991;18(10):1520–1528. PMID: 1765976.Warrick JH, Bhalla M, Schabel SI, Silver RM. High resolution computed tomography in early scleroderma lung disease. The Journal of Rheumatology. 1991;18(10):1520–1528. PMID: 1765976.Maher TM, Oballa E, Simpson JK, Porte J, Habgood A, Fahy WA, et al. An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study. The Lancet Respiratory Medicine. 2017;5(12):946–955. DOI: https://doi.org/10.1016/S2213-2600(17)30430-7.Maher TM, Oballa E, Simpson JK, Porte J, Habgood A, Fahy WA, et al. An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study. The Lancet Respiratory Medicine. 2017;5(12):946–955. DOI: https://doi.org/10.1016/S2213-2600(17)30430-7.Inoue Y, Kaner RJ, Guiot J, Maher TM, Tomassetti S, Moiseev S, et al. Diagnostic and prognostic biomarkers for chronic fibrosing interstitial lung diseases with a progressive phenotype. Chest. 2020;158(2):646–659. DOI: https://doi.org/10.1016/j.chest.2020.03.037.Inoue Y, Kaner RJ, Guiot J, Maher TM, Tomassetti S, Moiseev S, et al. Diagnostic and prognostic biomarkers for chronic fibrosing interstitial lung diseases with a progressive phenotype. Chest. 2020;158(2):646–659. DOI: https://doi.org/10.1016/j.chest.2020.03.037.Watase M, Mochimaru T, Kawase H, Shinohara H, Sagawa S, Ikeda T, et al. Diagnostic and prognostic biomarkers for progressive fibrosing interstitial lung disease. PLoS One. 2023;18(3):e0283288. DOI: https://doi.org/10.1371/journal.pone.0283288.Watase M, Mochimaru T, Kawase H, Shinohara H, Sagawa S, Ikeda T, et al. Diagnostic and prognostic biomarkers for progressive fibrosing interstitial lung disease. PLoS One. 2023;18(3):e0283288. DOI: https://doi.org/10.1371/journal.pone.0283288.Nathan N, Corvol H, Amselem S, Clement A. Biomarkers in Interstitial lung diseases. Paediatric Respiratory Reviews. 2015;16(4):219–224. DOI: https://doi.org/10.1016/j.prrv.2015.05.002.Nathan N, Corvol H, Amselem S, Clement A. Biomarkers in Interstitial lung diseases. Paediatric Respiratory Reviews. 2015;16(4):219–224. DOI: https://doi.org/10.1016/j.prrv.2015.05.002.Jee AS, Sahhar J, Youssef P, Bleasel J, Adelstein S, Nguyen M, et al. Review: Serum biomarkers in idiopathic pulmonary fibrosis and systemic sclerosis associated interstitial lung disease — frontiers and horizons. Pharmacology & Therapeutics. 2019;202:40–52. DOI: https://doi.org/10.1016/j.pharmthera.2019.05.014.Jee AS, Sahhar J, Youssef P, Bleasel J, Adelstein S, Nguyen M, et al. Review: Serum biomarkers in idiopathic pulmonary fibrosis and systemic sclerosis associated interstitial lung disease — frontiers and horizons. Pharmacology & Therapeutics. 2019;202:40–52. DOI: https://doi.org/10.1016/j.pharmthera.2019.05.014.

The authors declare that there are no conflicts of interest present.